Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASCO 2021

4 - 8 Jun 2021
Virtual, United States of America
Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC a...
Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China
Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC at ASCO 2021 ( Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China )
16 Jul 2021
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-...
Dr Michael Morris - Memorial Sloan Kettering Cancer Center and Weill Cornell Med...
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION) ( Dr Michael Morris - Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, USA )
15 Jul 2021
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNS...
Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )
6 Jul 2021
ASCO 2021: Lung roundup
Dr Luis Raez - Memorial Healthcare System, FL, USA
ASCO 2021: Lung roundup ( Dr Luis Raez - Memorial Healthcare System, FL, USA )
5 Jul 2021
FGFR as a tumour agnostic indicator and its importance in the diagnosis and trea...
Dr Christophe Massard and Prof Eva Compérat
FGFR as a tumour agnostic indicator and its importance in the diagnosis and treatment of multiple solid tumour types ( Dr Christophe Massard and Prof Eva Compérat )
1 Jul 2021
ASCO 2021: Precision and molecular reporting for prostate cancer
Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA
ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )
29 Jun 2021
Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative ch...
Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland
Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy ( Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland )
29 Jun 2021
COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory ...
Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA
COSMIC-311: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )
29 Jun 2021
Latest updates in exon 20 insertions focusing on targeted therapies, novel appro...
Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho
Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )
22 Jun 2021
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
COVID-19 and cancer: Highlights from ASCO 2021
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
COVID-19 and cancer: Highlights from ASCO 2021 ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refracto...
Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )
21 Jun 2021
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previ...
Dr John Byrd - The Ohio State University, Columbus, USA
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )
21 Jun 2021
Breast cancer roundup from ASCO 2021
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
18 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 4 and 5
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 4 and 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
16 Jun 2021
ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHS...
Prof Neeraj Agarwal - Huntsman Cancer Institute, University of Utah, Salt Lake ...
ADT plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed mHSPC ( Prof Neeraj Agarwal -  Huntsman Cancer Institute, University of Utah, Salt Lake City, USA )
15 Jun 2021
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Developments in metastatic hormone-sensitive prostate cancer
Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura-Maria...
Developments in metastatic hormone-sensitive prostate cancer ( Prof Karim Fizazi, Prof Alicia Morgans, Prof Neeraj Agarwal and Prof Laura-Maria Krabbe )
11 Jun 2021
Marizomib in combination with temozolomide-based radiochemotherapy for newly dia...
Dr Patrick Roth - University Hospital Zurich, Zurich, Switzerland
Marizomib in combination with temozolomide-based radiochemotherapy for newly diagnosed glioblastoma ( Dr Patrick Roth - University Hospital Zurich, Zurich, Switzerland )
11 Jun 2021
Pembrolizumab improves on chemo in MSI-H/dMMR mCRC
Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, Fran...
Pembrolizumab improves on chemo in MSI-H/dMMR mCRC ( Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, France )
11 Jun 2021
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC
Dr Christina Baik - University of Washington School of Medicine, Seattle, USA
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )
11 Jun 2021
PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to pr...
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian function ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
11 Jun 2021
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in t...
Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA
ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )
11 Jun 2021
IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy...
Prof Heather Wakelee - Stanford University, Stanford, USA
IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC ( Prof Heather Wakelee - Stanford University, Stanford, USA )
11 Jun 2021
Clinically sufficient vitamin D levels at breast cancer diagnosis and survival o...
Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA
Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes ( Prof Song Yao - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
10 Jun 2021
AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovia...
Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA
AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )
10 Jun 2021
Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial ...
Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA
Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )
10 Jun 2021
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...
Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )
10 Jun 2021
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecula...
Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )
10 Jun 2021
Adjuvant chemo following chemoradiation as treatment for locally advanced cervic...
Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia
Adjuvant chemo following chemoradiation as treatment for locally advanced cervical cancer compared to chemoradiation alone ( Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia )
10 Jun 2021
Tislelizumab in oesophageal cancer after systemic therapy
Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA
Tislelizumab in oesophageal cancer after systemic therapy ( Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA )
9 Jun 2021
HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with sel...
Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA
HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )
9 Jun 2021
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC
Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC ( Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA )
9 Jun 2021
PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men wi...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
PEACE-1: Abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo mCSPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
9 Jun 2021
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma
Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma ( Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA )
9 Jun 2021
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...
Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )
8 Jun 2021
Highlights from ASCO 2021
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC
Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany
PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 1
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve...
Dr Joshua Sabari and Dr Anna Minchom
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )
8 Jun 2021
Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction...
Prof Daniel Catenacci - University of Chicago, Chicago, USA
Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma ( Prof Daniel Catenacci - University of Chicago, Chicago, USA )
5 Jun 2021
Clinical trials participation is directly influenced by the information received...
Dr Daniel Vorobiof - Belong.Life, New York, USA
Clinical trials participation is directly influenced by the information received by cancer patients and caregivers ( Dr Daniel Vorobiof - Belong.Life, New York, USA )
4 Jun 2021
NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resect...
Dr Jonathan Spicer - McGill University, Montreal, Canada
NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )
4 Jun 2021
Incidence and trends of HPV-related cancers in the United States
Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San Francis...
Incidence and trends of HPV-related cancers in the United States ( Dr John Chan - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
4 Jun 2021
ASCO 2021: Latest on PARPi and other treatments for mCRPC
Dr Neal Shore and Prof Oliver Sartor
ASCO 2021: Latest on PARPi and other treatments for mCRPC ( Dr Neal Shore and Prof Oliver Sartor )
4 Jun 2021
mCRPC: Latest developments in diagnostics and combination therapies
Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor
mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )
4 Jun 2021
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally ad...
Dr Terence Friedlander - UCSF, San Francisco, USA
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )
4 Jun 2021
Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advan...
Dr Ian Chau - The Royal Marsden, London, UK
Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC ( Dr Ian Chau -  The Royal Marsden, London, UK )
4 Jun 2021
ASCO 2021: Renal cancer roundup
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2021
Olaparib improves disease-free survival in high-risk early-stage HER2-negative b...
Prof Andrew Tutt - Institute of Cancer Research, London, UK
Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )
4 Jun 2021
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy f...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2021
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-lin...
Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, ...
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
4 Jun 2021